Castleark Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-53,600
| Closed | -$6.4M | – | 309 |
|
|
2022
Q4 | $6.4M | Buy |
53,600
+830
| +2% | +$99.1K | 0.33% | 71 |
|
|
2022
Q3 | $5.61M | Sell |
52,770
-1,230
| -2% | -$131K | 0.31% | 73 |
|
|
2022
Q2 | $5.26M | Buy |
54,000
+8,760
| +19% | +$854K | 0.28% | 89 |
|
|
2022
Q1 | $4.24M | Buy |
+45,240
| New | +$4.24M | 0.18% | 124 |
|
|
2021
Q4 | – | Sell |
-1,405
| Closed | -$135K | – | 353 |
|
|
2021
Q3 | $135K | Hold |
1,405
| – | – | 0.01% | 307 |
|
|
2021
Q2 | $137K | Hold |
1,405
| – | – | ﹤0.01% | 314 |
|
|
2021
Q1 | $137K | Sell |
1,405
-1,775
| -56% | -$173K | ﹤0.01% | 312 |
|
|
2020
Q4 | $305K | Hold |
3,180
| – | – | 0.01% | 299 |
|
|
2020
Q3 | $306K | Sell |
3,180
-11,250
| -78% | -$1.08M | 0.01% | 297 |
|
|
2020
Q2 | $1.76M | Sell |
14,430
-43,542
| -75% | -$5.31M | 0.08% | 189 |
|
|
2020
Q1 | $5.02M | Sell |
57,972
-35,995
| -38% | -$3.12M | 0.3% | 101 |
|
|
2019
Q4 | $10.1M | Sell |
93,967
-10,058
| -10% | -$1.08M | 0.4% | 70 |
|
|
2019
Q3 | $9.37M | Buy |
+104,025
| New | +$9.37M | 0.38% | 92 |
|
|
2019
Q1 | – | Sell |
-15,775
| Closed | -$1.13M | – | 387 |
|
|
2018
Q4 | $1.13M | Sell |
15,775
-30,890
| -66% | -$2.2M | 0.05% | 257 |
|
|
2018
Q3 | $5.74M | Buy |
46,665
+4,195
| +10% | +$516K | 0.16% | 184 |
|
|
2018
Q2 | $4.17M | Sell |
42,470
-3,480
| -8% | -$342K | 0.13% | 209 |
|
|
2018
Q1 | $3.81M | Buy |
45,950
+16,330
| +55% | +$1.35M | 0.12% | 214 |
|
|
2017
Q4 | $2.3M | Buy |
+29,620
| New | +$2.3M | 0.07% | 251 |
|